The Latest Breaking News from HUM

Humana Inc (NYSE:HUM) has posted Q1 adjusted sales of $24.08 billion, beating the consensus of $23.51 billion. The benefits expense ratio increased from 86.4% to 85.9%, and the operating cost ratio increased from 12% to 9.7%.  Humana posted an adjusted EPS of $8.04, beating the consensus of $6.78 and $6.38 posted a…

  Humana (NYSE:HUM) reported its Q1 earnings results on Wednesday, April 27, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Humana Inc (NYSE:HUM) has agreed to divest a majority interest in the Hospice and Personal Care divisions of Humana's Kindred at Home (KAH Hospice) subsidiary to Clayton, Dubilier & Rice (CD&R). The divisions include patient-centered services for Hospice, Palliative, Community, and Personal Care.  Humana had previously indicated its intent to divest a majority…

Humana (NYSE:HUM) has outperformed the market over the past 10 years by 5.55% on an annualized basis producing an average annual return of 18.03%. Currently, Humana has a market capitalization of $59.08 billion.

UBS upgraded its rating of Humana (NYSE:HUM) to Buy with a price target of $520.00, changing its price target from $486.00 to $520.00. Shares of Humana are trading up 2.2% over the last 24 hours, at $458.92 per share. A move to $520.00 would account for a 13.31% increase from…

If history is any guide, there may be good fortune ahead for shares of Humana (NYSE:HUM). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Humana (NYSE:HUM) has outperformed the market over the past 5 years by 1.74% on an annualized basis producing an average annual return of 15.84%. Currently, Humana has a market capitalization of $55.72 billion.

Inflation has surged to multi-year highs, so the Fed is contemplating raising interest rates aggressively this year. And an increasing interest rate environment typically translates to revenue growth for financial companies, including insurers. Thus, we think it could be wise to bet on quality insurance stocks Cigna (CI), Humana (HUM),…

Humana (NYSE:HUM) has outperformed the market over the past 10 years by 5.66% on an annualized basis.

The pandemic-driven increase in health awareness and rising chronic diseases should drive the healthcare-plans industry’s growth. However, not all industry participants are well-positioned to gain in the near term. Clover Health (CLOV), with inconsistent financials and growth, is not expected to perform well. Therefore, fundamentally sound stocks in this space—UnitedHealth…

The rising aging population and the increasing spending on healthcare have been driving the health insurance industry’s growth. So, Humana (HUM) and Clover (CLOV) should benefit. But which of these two stocks is a better buy now? Read more to find out.